insights_auto
Bakit bumaba ang LGND 2.44%?
Tingnan ang Higit pang Detalyechevron_right
LGND:NASDAQ
Ligand Pharmaceuticals Inc
$303.53
arrow_downward
-2.44%(-7.60) 1D
$303.53
0.00% (0.00)
bedtimePagkalipas ng oras ng trabaho
Sarado: Okt 13, 4:00:01 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa LGND...
Buksan
$311.72
Mataas
$311.72
Mababa
$300.23
Mkt. cap
6.05B
Avg. na dami
248.12K
Dami
196.56K
P/E ratio
32.28
Mataas nang 52-wk
$326.63
Mababa nang 52-wk
$175.89
EPS
$9.40
Beta
1.06
Mga natitirang share
19.94M
Bilang ng mga empleyado
47
Buksan
$311.72
Mataas
$311.72
Mababa
$300.23
Mkt. cap
6.05B
Avg. na dami
248.12K
Dami
196.56K
P/E ratio
32.28
Mataas nang 52-wk
$326.63
Mababa nang 52-wk
$175.89
EPS
$9.40
Beta
1.06
Mga natitirang share
19.94M
Bilang ng mga empleyado
47
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Benzinga
·
13 oras ang nakalipas
Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Today
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
Tungkol sa Ligand Pharmaceuticals Inc
CEO-
Mga Empleyado47
ItinatagSet 1987
HeadquartersJupiter, Florida, Estados Unidos
Sektor-
Websiteligand.com